1 / 42

Diagnosis & Management of Growth Hormone Deficiency Consensus Workshop 17-21 October 1999

Growth Hormone Research Society. Diagnosis & Management of Growth Hormone Deficiency Consensus Workshop 17-21 October 1999. GRS Consensus Workshop. On behalf of Drs. Clayton, Cohen, Hintz, Laron, Sizonenko, and Tanaka, the GRS Council, and the attendees in the GRS Consensus meeting.

hashim
Download Presentation

Diagnosis & Management of Growth Hormone Deficiency Consensus Workshop 17-21 October 1999

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Growth Hormone Research Society Diagnosis & Management of Growth Hormone Deficiency Consensus Workshop 17-21 October 1999

  2. GRS Consensus Workshop On behalf of Drs. Clayton, Cohen, Hintz, Laron, Sizonenko, and Tanaka, the GRS Council, and the attendees in the GRS Consensus meeting

  3. GRS Consensus WorkshopObjectives • To formulate consensus guidelines for the diagnosis and treatment of children and adolescents with severe and moderate GH deficiency

  4. Participants to the Consensus Workshop • Pediatric & Adult Endocrinologists • Clinicians & Scientists • Representatives of LWPES, ESPE, JPES, APES, S-APES • Representatives from companies manufacturing rhGH • Participants from 13 countries • Totaling 44 • Pediatric & Adult Endocrinologists • Clinicians & Scientists • Representatives of LWPES, ESPE, JPES, APES, S-APES • Representatives from companies manufacturing rhGH • Participants from 13 countries • Totaling 44 • Pediatric & Adult Endocrinologists, Clinicians & Scientists • Representatives of LWPES, ESPE, JPES, APES, SAPES • Representatives from companies manufacturing rhGH • Participants from 13 countries • Totaling 44

  5. GRS consensus guidelinesDiagnosis and treatment of childhood GHD • Consensus document endorsed by GRS, Council of ESPE, LWPES, JSPE, SLEP, APEG • Consensus document accepted by JCEM • Publication expected Q4 2000

  6. GRS Consensus Workshop Part One Diagnosis of Growth Hormone Deficiency

  7. Auxological & Clinical Criteria (1) Short stature is defined as Height more than 2SD below the mean • History & Physical Exam : • Neonatal: Hypoglycemia, prolonged jaundice, microphallus, traumatic delivery • Cranial irradiation • Craniofacial midline abnormalities • Consanguinity &/or affected family member • Head trauma or CNS infection/infiltration

  8. Auxological & Clinical Criteria (2) • For immediate investigation : • Height > 3 SD below the mean • Height > 1.5 SD below mid-parental height • Height > 2 SD below mean& Height Velocity over 1 year > 1SD below mean for CAor Decrease in Ht SD > 0.5 over 1 yearin those aged more than 2 years of age

  9. Clinical & Auxological Criteria (3) • For immediate investigation : • In absence of short stature, Ht Velocity> 2 SD below the mean over 1 year or > 1.5 SD over 2 years • Signs of an intracranial lesion • Signs of multiple pituitary hormone deficiency • Neonatal symptoms & signs of GHD

  10. Clinical & Auxological Criteria (4) • Interpretation of Growth data : • Use relevant population standards • Whenever possible update standards • Express as Standard Deviation Scores rather than percentiles • Need for longitudinal velocity standards • Biological markers, such as Body Composition,Bone Density & Bone Markers are NOT discriminatory for GHD

  11. Evaluation for Genetic Disorders • Early onset of growth failure • Possible family history & consanguinity • Height > 3 SD below the mean • Extremely low GH response to provocative tests, including GHRH, & very low IGF-I and IGFBP-3 • Tests (e.g. for Prop-1, Pit-1, HESX-1, etc...) becoming available  Bank DNA respecting ethical & legal considerations

  12. Radiological Evaluation • Bone age on wrist XR • CNS imaging by MRI/CT • Suspected intracranial lesion • Optic nerve hypoplasia/SOD • Other structural/developmental anomaly • Confirmed IGHD/MPHD • Record • Pituitary height &/or volume, stalk anatomy • Position of posterior pituitary bright signal

  13. Biochemical Assessment of GHD (1) • Assay considerations • GH reference preparation 22kD rhGH (88/625 3IU = 1mg) • Need WHO preparation for rhIGF-I • Clinician should be aware of methodology & performance in the diagnosis • Recommend assays measuring 22kD hGH with monoclonal antibodies • Immunofunctional GH assay requires further evaluation

  14. Biochemical Assessment of GHD (2) • GH provocation tests • Limit number of provocative agents (Arginine, Clonidine, Glucagon, Insulin & l-Dopa), but limited reference data are presently available for each test • Traditionally diagnosis of GHD made with peak GH< 10g/LBUT this value needs revising for newer assays • Recognized that GH secretion is a continuum & that overlap exists in peak GH values between normal & GHD children

  15. Biochemical Assessment of GHD (3) • IGF-I & IGFBP-3 values • Use reference ranges standardized for age & sex • Values > 2SD below the mean strongly suggest an abnormality in GH axis • BUT values within the normal range are seen in GHD • In the absence of a Gold Standard for GHD, integrate ALL available data

  16. Biochemical Assessment of GHD (4) • Sex-Steroid Priming for GH Tests • NO CONSENSUS has been yet established • But it is recognized that GHD is very difficult to diagnose in the peripubertal period when GH levels are frequently low

  17. Biochemical Assessment of GHD (5) • Other tests of the GH axis • Urinary GH, serum IGF-II, IGFBP-2 & ALS may be useful in combination with other tests • Combination of Arginine & GHRH recognized as the most potent stimulus to GH • Evaluation of spontaneous GH secretion when GH & IGF data conflict, but Neurosecretory Dysfunction (without Cranial Radiotherapy) a rare diagnosis

  18. Biochemical Assessment of GHD (6) • Confounding factors • Nutritional status • Concomitant medication • Psychosocial conditions

  19. The Process of Evaluation of the GH-IGF Axis • Once a decision to test is made • Measure IGF-I/IGFBP-3 & carry out GH provocation tests • For suspected IGHD, perform two GH tests • For established pathology, do one only • Check other pituitary function • Be alert to evolving hormone deficits • The combination of Normal GH but low IGF-I/IGFBP-3 is recognized - May need to consider GH treatment • MRI (or CT) if GHD diagnosed

  20. Conclusions Part One • Diagnosis of Severe GHD is usually straightforward Well-defined clinical, auxological, biochemical & radiological abnormalities • Diagnosis of Moderate GHD can be associated with normal IGF axis & normal MRI • Diagnosis requires consideration of data from comprehensive assessment & investigation

  21. GRS Consensus Workshop Part Two Treatment of Growth Hormone Deficiency

  22. Indications and Goals of GHD Rx • Patients with proven GHD should be treated with rhGHas soon as possible after the diagnosis is made • Primary objectives of the therapy of GHD are:Normalization of height during childhood • Attainment of normal adult height • Normally growing patients with craniopharyngioma& GHD should be considered for therapy with GH for • Metabolic and body composition benefits • Enhancement of pubertal growth

  23. Mode of Administration of GH • Daily subcutaneously in the evening • The dosage of GH should be expressed in g (or mg)/kg/day • Consideration should be given to dosing in g/m2/day in patients with obesity

  24. GH Dosing • GH is routinely used in the range of 25-50 g/kg/day A dose-response relationship in terms of height velocity in the first two years of therapy has been clearly demonstrated within this range Under special circumstances, higher doses may be required.

  25. The use of Prediction Models • Prediction models of growth response might be useful for determination of the optimal individual starting dose • Prediction models are currently being investigated but need further evaluation

  26. Evaluation of Response to GH • The determination of the growth response to GH treatment is the single most important parameter in the monitoring of the child with GHD • Increase in height and change in height velocity are useful in clinical practice to assess the response to GH • For comparative purposes, data should be expressed as: the increase in (or ) height SD/year

  27. Monitoring GH-Rx • IGF levels in GHD • For assurance of compliance and safety, monitoring serum IGF-I and IGFBP-3 levels is useful, although they do not always correlate well with the growth response.

  28. Monitoring GH-Therapy Not indicated in Routine monitoring • Serum leptin, • Bone markers • GH antibodies • Lipid profiles • Fasting insulin • Bone age

  29. Summary for Monitoring GH Therapy • Close follow-up with a pediatric endocrinologist every 3-6 months, in partnership with the pediatrician or primary care physician • Determination of growth response (change in height SDS) • Monitoring serum IGF-I and IGFBP-3 levels • Screening for potential adverse effects • Evaluation of compliance • Consideration of dose adjustment based on IGF values, growth response, pubertal status, & comparison to growth prediction models

  30. Factors affecting the response to GH • Every effort should be made to diagnose and treat children at the youngest possible age • It is very important to maximize height with GH therapy before the onset of puberty • If this is achieved, then modulation of the GH dose during puberty may not be necessary

  31. Treatment of children entering puberty In the MPHD patient in whom puberty does not occur spontaneously, puberty should be initiated at the appropriate time after discussion with the patient GH dose escalation Combined GH & GnRH-agonists Not fully tested and cannot be recommended at this time Role of gender Role of body composition Need further investigations

  32. Management of MPHD • Patients with suspected or proven multiple pituitary hormone deficiencies should be managed similarly to patients with isolated GHD • However, attention should be given to correct clinical recognition, treatment, and monitoring of additional hormonal deficiencies (thyroxine, cortisol, sex steroids, and ADH) • In the patient with an initial diagnosis of isolated GHD, particularly those with an ectopic posterior pituitary or other developmental abnormalities, the clinician should be alert to the risk of the development of MPHD

  33. Safety Issues (1) • Treatment with GH may unmask underlying hypothyroidism • Significant side effects of GH treatment in children are very rare • These include:benign intracranial hypertension, prepubertal gynecomastia, arthralgia, edema

  34. Safety Issues (2) • Careful history and physical examination are adequate to identify the presence of side-effects • Management of these side effects may include transient reduction of dosage or temporary discontinuation of GH • In the absence of other risk factors there is no evidence that GH recipients have increased risk ofLeukemia,Brain tumor recurrence,Slipped capital femoral epiphysis,Diabetes

  35. Safety Issues (3) • Tumor survivors receiving GH should be followed in conjunction with an oncologistand a neurosurgeon when appropriate • There is no evidence that GH replacement needs to be discontinued during intercurrent illness

  36. Re-testing (1) • After attainment of final height, re-testing of the GH-IGF axis, using the adult GHD diagnostic criteria as defined by the Growth Hormone Research Society (GRS) consensus workshop on adult GHD in 1997 at Port Stephens should be undertaken by the pediatric endocrinologist using standard GH stimulation tests after an appropriate interval of 1 to 3 months off GH therapy

  37. Re-testing (2) • In places where an insulin tolerance test is mandatory for the patient to qualifyfor further GH therapy, this test should be performed • At the time of re-testing, other pituitary hormones and an IGF-I should also be measured

  38. Transition to adult GHD care (1) • GH deficiency may or may not persist into adult life • GH has major metabolic actions, important for body composition and health in adults as in children • The opportunity should be taken to assess body composition, bone mineral density, fasting lipids and insulin, before and after discontinuation of GH therapy

  39. Transition to adult GHD care (2) • When the diagnosis of adult GHD is established, continuation of GH therapy is recommended • Caution should be exercised when considering the decision of continuing GH therapy in conditions where there is a known risk of diabetes or malignancy

  40. Conclusions regarding consensus (1) • The approach to the diagnosis and treatment of GH deficiency in children is evolving • Clearly, many additional evidence-based clinical studies on the diagnosis and treatment of GHD will undoubtedly modify our approach

  41. Conclusions regarding consensus (2) • It will be the goal of the Growth Hormone Research Society, as well as the Pediatric Endocrine societies and Bodies, which have endorsed this document, to amend and revise this statement in coming years

  42. GRS Consensus Workshop

More Related